Ga-68 FAPI PET Before Immunotherapy (FAPBI)

June 14, 2024

Primary Outcome Measures

prediction of immunotherapy response with SUVmax measured with Ga-68 FAPI PET before immunotherapy
prediction of immunotherapy response with total FAPI volume measured with Ga-68 FAPI PET before immunotherapy
prediction of immunotherapy response with total lesion FAPI uptake measured with Ga-68 FAPI PET before immunotherapy

Inclusion Criteria

Having a histopathologically confirmed diagnosis of
Pleural Mesolthelioma
Patients scheduled for immunotherapy with anti-PDL-1 and/or anti-CTLA-4 antibodies as first or second line therapy
Patients who gave informed consent form to participate in the study

Exclusion Criteria

ECOG>2
Patients who did not provide informed consent form to participate in the study

CONTACT INFORMATION

Name*

First Last

Email*

Phone*

Address*

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Have you received a diagnosis?*

Yes

DIAGNOSIS

Diagnosis?*

Date of Diagnosis*

Comments*

Comments

This field is for validation purposes and should be left unchanged.

Quick Facts

Accepts Healthy Volunteers
Ages Available for Study
ClinicalTrials.gov Identifier
Collaborators
Contacts(s)
Location(s)
Estimated Enrollment
Estimated Study Start Date
Estimated Primary Completion Dates
Full Title
Genders Eligible for Study
Investigator(s)
Last Updated
Other Contact